Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00514306 · ClinicalTrials.gov registry record · Phase 1
Study of Intermittent OSI-906 Dosing
A Phase 1 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT00514306 is a Phase 1 study that has completed, run by Astellas Pharma. The registered enrollment target is 79 participants.
The verdict
NCT00514306, a Phase 1 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
Interventions
- DRUG OSI-906
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2007-07-05 |
| Est. Completion | 2010-09-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00514306
The ClinicalTrials.gov registry entry for NCT00514306 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which OSI-906 is the first listed.
NCT00514306 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00514306 about?
NCT00514306 is a clinical study titled "Study of Intermittent OSI-906 Dosing". Multicenter, open-label, phase 1, cohort dose escalation study to determine the maximum tolerated dose (MTD) of 3 intermittent OSI-906 dosing schedules.
What is the current status of trial NCT00514306?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2007-07-05. Estimated completion is 2010-09-20.
What interventions are being tested in trial NCT00514306?
The interventions under investigation include: OSI-906 (DRUG).
Who is sponsoring clinical trial NCT00514306?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.